VERTEX PHARMACEUTICALS INC / MA 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Nov 7, 2014
Insider Transaction Report
Form 4
Connolly Thomas
SVP, Human Resources
Transactions
- Exercise/Conversion
Common Stock
2014-11-05$45.11/sh+937$42,268→ 35,832 total - Sale
Common Stock
2014-11-05$112.07/sh−637$71,389→ 35,195 total - Sale
Common Stock
2014-11-05$113.13/sh−200$22,626→ 34,995 total - Sale
Common Stock
2014-11-05$114.31/sh−100$11,431→ 34,895 total - Exercise/Conversion
Stock Option (right to buy)
2014-11-05−937→ 8,438 totalExercise: $45.11Exp: 2023-02-04→ Common Stock (937 underlying)
Holdings
- 150(indirect: By 401(k))
Common Stock
Footnotes (5)
- [F1]Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $112.07 (range $111.69 to $112.46).
- [F3]Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $113.13 (range $112.89 to $113.37).
- [F5]The option vests in 16 quarterly installments from 02/05/2013.